Treatment of patients with radioiodine refractory, differentiated thyroid carcinoma. A Consensus Statement
There is no clear standard therapy for patients with radioactive iodine (131I)-refractory locally advanced or metastatic differentiated thyroid cancer. The therapeutic options for this indication have expanded with the recently approved multiple kinase inhibitor sorafenib. Recommendations for the definition and the management of iodine refractory patients were worked up by an interdisciplinary expert panel, consisting of endocrine surgeons, medical oncologists and nuclear medicine specialists.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:54 |
|---|---|
| Enthalten in: |
Nuklearmedizin. Nuclear medicine - 54(2015), 3 vom: 01., Seite 125-30 |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
Therapie des Patienten mit Radioiod-refraktärem, differenziertem Schilddrüsenkarzinom. Ein Konsensusstatement |
|---|
| Beteiligte Personen: |
Lindner, Christina [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 21.03.2016 Date Revised 03.12.2018 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3413/Nukmed-0688-14-07 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM243767978 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM243767978 | ||
| 003 | DE-627 | ||
| 005 | 20231224133229.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.3413/Nukmed-0688-14-07 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0812.xml |
| 035 | |a (DE-627)NLM243767978 | ||
| 035 | |a (NLM)25421138 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Lindner, Christina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatment of patients with radioiodine refractory, differentiated thyroid carcinoma. A Consensus Statement |
| 246 | 3 | 3 | |a Therapie des Patienten mit Radioiod-refraktärem, differenziertem Schilddrüsenkarzinom. Ein Konsensusstatement |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.03.2016 | ||
| 500 | |a Date Revised 03.12.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a There is no clear standard therapy for patients with radioactive iodine (131I)-refractory locally advanced or metastatic differentiated thyroid cancer. The therapeutic options for this indication have expanded with the recently approved multiple kinase inhibitor sorafenib. Recommendations for the definition and the management of iodine refractory patients were worked up by an interdisciplinary expert panel, consisting of endocrine surgeons, medical oncologists and nuclear medicine specialists | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Radioactive iodine-refractoriness | |
| 650 | 4 | |a sorafenib | |
| 650 | 4 | |a thyroid cancer | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Iodine Radioisotopes |2 NLM | |
| 650 | 7 | |a Phenylurea Compounds |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Radiopharmaceuticals |2 NLM | |
| 650 | 7 | |a Niacinamide |2 NLM | |
| 650 | 7 | |a 25X51I8RD4 |2 NLM | |
| 650 | 7 | |a Sorafenib |2 NLM | |
| 650 | 7 | |a 9ZOQ3TZI87 |2 NLM | |
| 700 | 1 | |a Dierneder, J |e verfasserin |4 aut | |
| 700 | 1 | |a Pall, G |e verfasserin |4 aut | |
| 700 | 1 | |a Pirich, C |e verfasserin |4 aut | |
| 700 | 1 | |a Hoffmann, M |e verfasserin |4 aut | |
| 700 | 1 | |a Raderer, M |e verfasserin |4 aut | |
| 700 | 1 | |a Becherer, A |e verfasserin |4 aut | |
| 700 | 1 | |a Niederle, B |e verfasserin |4 aut | |
| 700 | 1 | |a Lipp, R |e verfasserin |4 aut | |
| 700 | 1 | |a Lind, P |e verfasserin |4 aut | |
| 700 | 1 | |a Gallowitsch, H |e verfasserin |4 aut | |
| 700 | 1 | |a Romeder, F |e verfasserin |4 aut | |
| 700 | 1 | |a Virgolini, I |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nuklearmedizin. Nuclear medicine |d 1993 |g 54(2015), 3 vom: 01., Seite 125-30 |w (DE-627)NLM00033619X |x 0029-5566 |7 nnns |
| 773 | 1 | 8 | |g volume:54 |g year:2015 |g number:3 |g day:01 |g pages:125-30 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3413/Nukmed-0688-14-07 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 54 |j 2015 |e 3 |b 01 |h 125-30 | ||